Treatment progress of peripheral T-cell lymphoma
10.3760/cma.j.cn115356-20210105-00004
- VernacularTitle:外周T细胞淋巴瘤治疗进展
- Author:
Zhen HE
;
Jianyong LI
;
Lei FAN
- From:
Journal of Leukemia & Lymphoma
2021;30(2):71-73
- CountryChina
- Language:Chinese
-
Abstract:
Peripheral T-cell lymphoma (PTCL) is a relatively common subtype of non-Hodgkin lymphoma in China. PTCL is clinically highly aggressive, and it progresses rapidly. The current treatment methods are ineffective and the overall prognosis is poor. The 62nd American Society of Hematology Annual Meeting reported on the progress of PTCL molecular targeted therapy and immunotherapy, including programmed death receptor 1/programmed death receptor ligand 1 antibodies, JAK inhibitors, brentuximab vedotin, etc. These novel drugs bring a better prospect for patients.
